실시간
Clinical OMICsGenome Wide Analysis Broadens Genetic Knowledge of AnxietyFierceBiotechGSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancerLabiotechPharma in Spain: why global investors and innovators are moving inEndpoints NewsGSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B10x Genomics Blog10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman - Stock Titan10x Genomics Blog10x Genomics (TXG) awards 8,829 RSUs to board director - Stock Titan10x Genomics News10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs - Stock Titan10x Genomics News10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings - Stock Titan10x Genomics News10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com10x Genomics Blog10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda - Stock TitanFierceBiotechCity aims to lay foundation for RNAi renaissance with nearly $100M series B
Recursion 2026년 4월 24일

Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com Canada

Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com Canada

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.